MX2020005200A - Novedoso receptor de celulas t gamma delta y su ligando. - Google Patents
Novedoso receptor de celulas t gamma delta y su ligando.Info
- Publication number
- MX2020005200A MX2020005200A MX2020005200A MX2020005200A MX2020005200A MX 2020005200 A MX2020005200 A MX 2020005200A MX 2020005200 A MX2020005200 A MX 2020005200A MX 2020005200 A MX2020005200 A MX 2020005200A MX 2020005200 A MX2020005200 A MX 2020005200A
- Authority
- MX
- Mexico
- Prior art keywords
- tcr
- cell
- ligand
- clone
- vector
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 2
- 102000011778 gamma-delta T-Cell Antigen Receptors Human genes 0.000 title 1
- 108010062214 gamma-delta T-Cell Antigen Receptors Proteins 0.000 title 1
- 108091008874 T cell receptors Proteins 0.000 abstract 11
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 11
- 210000004027 cell Anatomy 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 230000002163 immunogen Effects 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hematology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1719169.3A GB201719169D0 (en) | 2017-11-20 | 2017-11-20 | Novel T-cell receptor and ligand |
| PCT/GB2018/053321 WO2019097244A1 (en) | 2017-11-20 | 2018-11-16 | Novel gamma delta t-cell receptor and its ligand |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020005200A true MX2020005200A (es) | 2020-08-20 |
Family
ID=60805814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005200A MX2020005200A (es) | 2017-11-20 | 2018-11-16 | Novedoso receptor de celulas t gamma delta y su ligando. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11850264B2 (https=) |
| EP (1) | EP3713954A1 (https=) |
| JP (1) | JP2021505190A (https=) |
| KR (1) | KR20200085776A (https=) |
| CN (1) | CN111372944A (https=) |
| AU (1) | AU2018369698A1 (https=) |
| BR (1) | BR112020007469A2 (https=) |
| CA (1) | CA3079156A1 (https=) |
| EA (1) | EA202091276A1 (https=) |
| GB (1) | GB201719169D0 (https=) |
| IL (1) | IL274482A (https=) |
| MX (1) | MX2020005200A (https=) |
| SG (1) | SG11202002993UA (https=) |
| WO (1) | WO2019097244A1 (https=) |
| ZA (1) | ZA202002417B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230226183A1 (en) * | 2020-01-15 | 2023-07-20 | The Regents Of The University Of California | Compositions and methods for altering gamma delta t cell activity |
| EP4059955A1 (en) | 2021-03-19 | 2022-09-21 | Medizinische Hochschule Hannover | Hla-dr-specific gamma delta tcr constructs and use thereof |
| EP4472742A1 (en) | 2022-02-03 | 2024-12-11 | University College Cardiff Consultants Limited | Novel t-cell receptor |
| US20240043496A1 (en) * | 2022-07-26 | 2024-02-08 | Gadeta B.V. | Delta t-cell or gamma receptor chains or parts thereof for treating ovarian cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260223A (en) * | 1986-07-03 | 1993-11-09 | President & Fellows Of Harvard College | Methods for detection of human gamma, γ T cell receptor |
| WO1996013593A2 (en) * | 1994-10-26 | 1996-05-09 | Procept, Inc. | Soluble single chain t cell receptors |
| WO1999060120A2 (en) | 1998-05-19 | 1999-11-25 | Avidex Limited | Soluble t cell receptor |
| AU2002308481A1 (en) * | 2001-05-01 | 2002-11-11 | Senomyx, Inc. | High throughput cell-based assay for monitoring sodium channel activity and discovery of salty taste modulating compounds |
| AU2002359666A1 (en) * | 2001-12-10 | 2003-06-23 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
| CN1842709A (zh) * | 2003-07-10 | 2006-10-04 | 塞诺米克斯公司 | 使用表达人的ENaC的卵母细胞的改进的电生理测定法和用于在使用膜电位报告染料的测定中提高ENaC增强子功效的PHENAMIL的用途 |
| WO2013155406A1 (en) * | 2012-04-12 | 2013-10-17 | The Chinese University Of Hong Kong | Contragestion and treating inflammation by modulating sodium channel activity in the epithelium |
| WO2015121454A1 (en) * | 2014-02-14 | 2015-08-20 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| PL3119807T3 (pl) * | 2014-03-19 | 2019-09-30 | Cellectis | Specyficzne wobec cd123 chimeryczne receptory antygenowe do immunoterapii nowotworów |
| MX2016014434A (es) | 2014-05-13 | 2017-02-23 | Chugai Pharmaceutical Co Ltd | Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion. |
| WO2016016344A1 (en) | 2014-07-29 | 2016-02-04 | Cellectis | Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy |
| DK3271382T3 (da) * | 2015-03-16 | 2020-05-04 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Fremgangsmåde til detektion af nye immunogene T-celleepitoper og isolering af nye antigenspecifikke T-cellereceptorer ved hjælp af et MHC-cellebibliotek |
-
2017
- 2017-11-20 GB GBGB1719169.3A patent/GB201719169D0/en not_active Ceased
-
2018
- 2018-11-16 SG SG11202002993UA patent/SG11202002993UA/en unknown
- 2018-11-16 EP EP18808079.0A patent/EP3713954A1/en active Pending
- 2018-11-16 EA EA202091276A patent/EA202091276A1/ru unknown
- 2018-11-16 KR KR1020207014073A patent/KR20200085776A/ko not_active Ceased
- 2018-11-16 AU AU2018369698A patent/AU2018369698A1/en not_active Abandoned
- 2018-11-16 BR BR112020007469-1A patent/BR112020007469A2/pt not_active IP Right Cessation
- 2018-11-16 MX MX2020005200A patent/MX2020005200A/es unknown
- 2018-11-16 CN CN201880074771.1A patent/CN111372944A/zh active Pending
- 2018-11-16 WO PCT/GB2018/053321 patent/WO2019097244A1/en not_active Ceased
- 2018-11-16 CA CA3079156A patent/CA3079156A1/en active Pending
- 2018-11-16 JP JP2020544990A patent/JP2021505190A/ja active Pending
-
2020
- 2020-05-04 ZA ZA2020/02417A patent/ZA202002417B/en unknown
- 2020-05-06 IL IL274482A patent/IL274482A/en unknown
- 2020-05-19 US US16/877,928 patent/US11850264B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202002417B (en) | 2021-07-28 |
| US11850264B2 (en) | 2023-12-26 |
| US20200316124A1 (en) | 2020-10-08 |
| CA3079156A1 (en) | 2019-05-23 |
| AU2018369698A1 (en) | 2020-04-30 |
| JP2021505190A (ja) | 2021-02-18 |
| SG11202002993UA (en) | 2020-06-29 |
| BR112020007469A2 (pt) | 2020-11-03 |
| EA202091276A1 (ru) | 2020-09-04 |
| WO2019097244A1 (en) | 2019-05-23 |
| IL274482A (en) | 2020-06-30 |
| EP3713954A1 (en) | 2020-09-30 |
| KR20200085776A (ko) | 2020-07-15 |
| CN111372944A (zh) | 2020-07-03 |
| GB201719169D0 (en) | 2018-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004334A (es) | Receptor de celulas t novedoso. | |
| MX2020005651A (es) | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. | |
| PH12019500436A1 (en) | Adenovirus armed with bispecific t cell engager (bite) | |
| CO2018005695A2 (es) | Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y usos de estas | |
| MX2018002043A (es) | ANTICUERPOS ANTI-BCMA, MOLíCULAS DE UNIíN A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS. | |
| CL2017000515A1 (es) | Cd123 agentes enlazadores y su uso | |
| CO2019001114A2 (es) | Antianticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de estas | |
| BR112018067368A2 (pt) | terapia de combinação com anticorpos anti-cd73 | |
| MX2017007321A (es) | Terapias de combinacion. | |
| MX2020005200A (es) | Novedoso receptor de celulas t gamma delta y su ligando. | |
| PH12017501774A1 (en) | Compositions comprising a combination of an anti-pd-1 antibody and another antibody | |
| MX2018000347A (es) | Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. | |
| MD4716B1 (ro) | Anticorpi anti-LAG3 şi fragmente de legare a antigenului | |
| MX385338B (es) | Combinación de vacunación e inhibición de la trayectoria pd-1. | |
| MX385543B (es) | Uso de un anticuerpo biespecífico para tratar cáncer de linfocitos b. | |
| BR112016020953A2 (pt) | composto, kit, composição farmacêutica, uso de composto, método de tratamento e invenção | |
| MX2017012615A (es) | Anticuerpo anti-notch4 humano. | |
| PH12020550598A1 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells | |
| HK1251481A1 (zh) | 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法 | |
| BR112018074748A2 (pt) | composição terapêutica biespecífica de redirecionamento de células t, e método de tratamento de câncer gp100 positivo em um paciente | |
| HK1253098A1 (zh) | 用於治疗癌症的mdm2抑制剂的给药方案 | |
| MX2016014826A (es) | Conjugados de peptido-curcumina y formulaciones de los mismos. | |
| MX2019013071A (es) | Metodo de tratamiento inmunoterapeutico de un tumor. | |
| MX2017016183A (es) | Vacuna de adn que dirige vegfr-2 para terapia de combinacion. | |
| MX386476B (es) | Agente estimulador del receptor 1b de 5-hidroxitriptamina para mejorar el potencial de injerto in vivo. |